玻璃体腔注射地塞米松植入物在玻璃体切割术和未行玻璃体切割术的眼中治疗糖尿病性黄斑水肿的效果比较
Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.
作者信息
Çevik Sadık Görkem, Yılmaz Sami, Çevik Mediha Tok, Akalp Fatma Düriye, Avcı Remzi
机构信息
Department of Ophthalmology, Yüksek Ihtisas Research and Training Hospital, Bursa, Turkey.
Retina Eye Hospital, Bursa, Turkey.
出版信息
J Ophthalmol. 2018 Apr 22;2018:1757494. doi: 10.1155/2018/1757494. eCollection 2018.
Abstract
PURPOSE
To compare the effectiveness of sustained-release dexamethasone (DEX) intravitreal implant in nonvitrectomized eyes and vitrectomized eyes with diabetic macular edema (DME).
METHODS
A retrospective review of the medical records of 40 eyes of 30 consecutive patients with diabetic macular edema who underwent intravitreal DEX implant injection. Patients were divided into 2 subgroups: 31 eyes that were nonvitrectomized (group 1) and 9 eyes that had previously undergone standard pars plana vitrectomy (group 2). The main outcome measures were BCVA and foveal thickness (FT).
RESULTS
A significant improvement was seen in BCVA in both group 1 and group 2 at the 1st, 2nd, and 6th months after treatment with DEX implant ( < 0.05). In group 1, a significant reduction in FT was observed at the 1st, 2nd, and 6th months ( < 0.05). In group 2, a significant reduction in FT was seen at the 1st and 2nd months ( < 0.05), but the reduction rate at the 6th month after the injection was not statistically significant ( = 0.06).
CONCLUSION
DEX implant is effective for the treatment of diabetic macular edema, and the effectiveness of the drug is similar in vitrectomized and nonvitrectomized eyes.
摘要
目的
比较缓释地塞米松（DEX）玻璃体内植入物在未行玻璃体切割术的眼和已行玻璃体切割术的糖尿病性黄斑水肿（DME）眼中的疗效。
方法
回顾性分析30例连续接受玻璃体内DEX植入物注射的糖尿病性黄斑水肿患者的40只眼的病历。患者分为2个亚组：31只未行玻璃体切割术的眼（第1组）和9只先前已行标准平坦部玻璃体切割术的眼（第2组）。主要观察指标为最佳矫正视力（BCVA）和黄斑中心凹厚度（FT）。
结果
在使用DEX植入物治疗后的第1、2和6个月，第1组和第2组的BCVA均有显著改善（<0.05）。在第1组中，第1、2和6个月时FT显著降低（<0.05）。在第2组中，第1和2个月时FT显著降低（<0.05），但注射后第6个月的降低率无统计学意义（=0.06）。
结论
DEX植入物对糖尿病性黄斑水肿有效，且该药物在已行玻璃体切割术的眼和未行玻璃体切割术的眼中疗效相似。
相似文献
1
Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.玻璃体腔注射地塞米松植入物在玻璃体切割术和未行玻璃体切割术的眼中治疗糖尿病性黄斑水肿的效果比较
J Ophthalmol. 2018 Apr 22;2018:1757494. doi: 10.1155/2018/1757494. eCollection 2018.
2
Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema.玻璃体切除眼与非玻璃体切除眼内注射地塞米松植入物治疗持续性糖尿病性黄斑水肿患者的疗效比较
J Ocul Pharmacol Ther. 2014 Nov;30(9):709-16. doi: 10.1089/jop.2014.0010. Epub 2014 Sep 26.
3
Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis.地塞米松植入物在接受玻璃体切割术和未接受玻璃体切割术的糖尿病性黄斑水肿眼中的疗效和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2022 Dec 1;13:1029584. doi: 10.3389/fphar.2022.1029584. eCollection 2022.
4
Effect of dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes of Taiwanese patients with treatment-naïve diabetic macular edema.台湾地区未经玻璃体切割术和玻璃体切割术治疗的初治糖尿病黄斑水肿患者玻璃体内植入地塞米松的疗效。
J Formos Med Assoc. 2020 Nov;119(11):1619-1625. doi: 10.1016/j.jfma.2020.04.014. Epub 2020 May 30.
5
Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.玻璃体内注射190μg醋酸氟轻松植入剂（ILUVIEN®）治疗慢性糖尿病性黄斑水肿：玻璃体切割术眼与未行玻璃体切割术眼的比较
Ophthalmic Res. 2018;59(2):68-75. doi: 10.1159/000484091. Epub 2017 Dec 16.
6
Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study.在一项真实世界研究中评估玻璃体切割和非玻璃体切割眼玻璃体内植入地塞米松疗效和安全性。
J Ocul Pharmacol Ther. 2018 Oct;34(8):596-602. doi: 10.1089/jop.2018.0007. Epub 2018 Aug 17.
7
Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes.玻璃体腔注射地塞米松植入物治疗玻璃体切割术后糖尿病性黄斑水肿的疗效
Turk J Ophthalmol. 2019 Dec 31;49(6):323-327. doi: 10.4274/tjo.galenos.2019.95226.
8
Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis.玻璃体内注射雷珠单抗治疗非玻璃体切割和玻璃体切割的糖尿病性黄斑水肿的疗效：一项两年回顾性分析。
J Ophthalmol. 2020 Aug 6;2020:2561251. doi: 10.1155/2020/2561251. eCollection 2020.
9
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.玻璃体内注射缓释地塞米松植入物在玻璃体切割眼和非玻璃体切割眼中的药代动力学。
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4605-9. doi: 10.1167/iovs.10-6387.
10
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes.0.19毫克醋酸氟轻松和0.7毫克地塞米松玻璃体内植入物治疗玻璃体切除术后眼糖尿病性黄斑水肿的真实世界回顾性比较
Clin Ophthalmol. 2019 Sep 9;13:1751-1759. doi: 10.2147/OPTH.S201611. eCollection 2019.
引用本文的文献
1
Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center.用于葡萄膜炎的曲安奈德植入剂：在三级中心剖析应答者和非应答者的结果
Biomedicines. 2024 May 16;12(5):1106. doi: 10.3390/biomedicines12051106.
2
Centrifuged-Concentrated Intravitreal Slurry Triamcinolone Acetonide: An Inexpensive, Easy, and Viable Alternative to Long-Term Steroid Delivery.离心浓缩玻璃体内曲安奈德混悬液：一种用于长期类固醇给药的廉价、简便且可行的替代方法。
J Vitreoretin Dis. 2020 Sep 2;5(1):15-31. doi: 10.1177/2474126420943417. eCollection 2021 Jan-Feb.
3
Diabetic Macular Oedema Guidelines: An Australian Perspective.糖尿病性黄斑水肿指南：澳大利亚视角
J Ophthalmol. 2023 Feb 14;2023:6329819. doi: 10.1155/2023/6329819. eCollection 2023.
4
Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis.地塞米松植入物在接受玻璃体切割术和未接受玻璃体切割术的糖尿病性黄斑水肿眼中的疗效和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2022 Dec 1;13:1029584. doi: 10.3389/fphar.2022.1029584. eCollection 2022.
5
One-Month Outcomes of Intravitreal Anti-VEGF vs. Dexamethasone Implant in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes.玻璃体切除术后眼内注射抗血管内皮生长因子（anti-VEGF）与地塞米松植入治疗糖尿病性黄斑水肿的1个月疗效
Front Med (Lausanne). 2022 Jun 14;9:895220. doi: 10.3389/fmed.2022.895220. eCollection 2022.
6
Evaluation of the Effect of Intravitreal Dexamethasone (Ozurdex) Implant on Intraocular Pressure in Vitrectomized and Non-Vitrectomized Eyes with Macular Edema.评价玻璃体内注射地塞米松（Ozurdex）植入物对伴有黄斑水肿的玻璃体切割眼和非玻璃体切割眼眼内压的影响。
Turk J Ophthalmol. 2021 Dec 28;51(6):365-372. doi: 10.4274/tjo.galenos.2021.77864.
7
Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema.玻璃体内注射地塞米松植入物与雷珠单抗治疗玻璃体切除术后糖尿病性黄斑水肿的比较
J Ophthalmol. 2021 Sep 10;2021:8882539. doi: 10.1155/2021/8882539. eCollection 2021.
8
Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov-model.地塞米松和曲安奈德治疗芬兰糖尿病性黄斑水肿的成本效果：马尔可夫模型。
Acta Ophthalmol. 2021 Nov;99(7):e1146-e1153. doi: 10.1111/aos.14745. Epub 2021 Jan 9.
9
Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema.地塞米松植入物治疗难治性糖尿病性黄斑水肿的真实生活经验
Clin Ophthalmol. 2019 Dec 27;13:2583-2590. doi: 10.2147/OPTH.S232549. eCollection 2019.
10
Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes.玻璃体腔注射地塞米松植入物治疗玻璃体切割术后糖尿病性黄斑水肿的疗效
Turk J Ophthalmol. 2019 Dec 31;49(6):323-327. doi: 10.4274/tjo.galenos.2019.95226.
本文引用的文献
1
DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF RECALCITRANT MACULAR EDEMA AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR.地塞米松眼内植入物治疗孔源性视网膜脱离修复后难治性黄斑水肿。
Retina. 2018 Jun;38(6):1084-1090. doi: 10.1097/IAE.0000000000001720.
2
Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes.玻璃体内缓释类固醇植入物用于治疗视网膜前膜手术切除后黄斑水肿
Ophthalmologica. 2017;237(4):232-237. doi: 10.1159/000464259. Epub 2017 May 3.
3
Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema.玻璃体内注射地塞米松植入物治疗术后黄斑水肿
Ophthalmologica. 2016;236(4):181-185. doi: 10.1159/000448057. Epub 2016 Dec 3.
4
Short-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy.玻璃体内注射地塞米松植入物对接受过玻璃体切割术、患有顽固性糖尿病性黄斑水肿且先前接受过抗血管内皮生长因子治疗的眼睛的短期疗效。
J Ophthalmic Vis Res. 2016 Apr-Jun;11(2):183-7. doi: 10.4103/2008-322X.183928.
5
COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.玻璃体切除术联合玻璃体内地塞米松（Ozurdex）缓释植入物
Retina. 2016 Nov;36(11):2087-2092. doi: 10.1097/IAE.0000000000001063.
6
[Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy].玻璃体内注射地塞米松植入物治疗玻璃体切除术后持续性黄斑水肿
Ophthalmologe. 2016 Jul;113(7):581-8. doi: 10.1007/s00347-016-0223-y.
7
Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.雷珠单抗和阿柏西普：玻璃体切除和未切除玻璃体的猕猴眼中的眼内药代动力学及其对房水VEGF水平的影响
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6501-5. doi: 10.1167/iovs.15-17279.
8
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.雷珠单抗联合即时或延期激光治疗抗血管内皮生长因子治疗前已行玻璃体切割术的糖尿病性黄斑水肿眼
Retina. 2015 Dec;35(12):2516-28. doi: 10.1097/IAE.0000000000000617.
9
Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel.使用可注射且可生物降解的热凝胶进行地塞米松的玻璃体内持续给药。
Acta Biomater. 2015 Sep;23:271-281. doi: 10.1016/j.actbio.2015.05.005. Epub 2015 May 21.
10
Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular Edema.地塞米松植入物用于初治或难治性糖尿病性黄斑水肿患者
Ophthalmologica. 2015;233(3-4):176-85. doi: 10.1159/000371770. Epub 2015 Feb 6.
Zotero 插件